“Crohn’s Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.

Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).

Some of the key takeaways from the Crohn’s Disease Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years. 

• Crohn’s Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn’s Disease treatment 

• Emerging Crohn’s Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years. 

• In May 2024, In Eli Lilly and Company’s (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderate to severe Crohn’s disease, regardless of prior biologic treatment failure, experienced statistically significant and clinically meaningful improvements in various clinical and endoscopic measures after one year of treatment with mirikizumab compared to placebo.

• In March 2024, Developed by Janssen Biotech, Stelara is a biologic therapy used to treat various conditions, such as moderate to severely active Crohn’s disease, active ulcerative colitis (UC), active psoriatic arthritis, and plaque psoriasis. It can be administered either subcutaneously or intravenously. The subcutaneous injection comes in two formulations: 45mg/0.5ml and 90mg/ml, both available in single-dose prefilled syringes.

• In May 2023, For those with moderate to severe active Crohn’s disease who did not respond well to or were intolerant of one or more tumour necrosis factor blockers, the FDA has approved Rinvoq (upadacitinib). The first oral medicine for the management of Crohn’s disease that has received FDA approval is called Rinvoq.

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).

Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight

Emerging Crohn’s Disease Drugs Under Different Phases of Clinical Development Include:

• MORF 057: Morphic Therapeutic

• OTL-104: Orchard Therapeutics

• TP-317: Thetis Pharmaceuticals

• AZD 7798: AstraZeneca

• IMU 856: Immunic

• CBP-307: Suzhou Connect Biopharmaceuticals

• PF-06651600: Pfizer

• Deucravacitinib: Bristol-Myers Squibb

• E6011: Eisai Inc

• Guselkumab: Janssen Pharmaceutical

• Mirikizumab: Eli Lilly and Company

• Filgotinib: Gilead Sciences

• RHB-104: RedHill Biopharma

• Ozanimod: Celgene Corporation

• Brazikumab: AstraZeneca

Crohn’s Disease Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Crohn’s Disease Molecule Type

Crohn’s Disease Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Crohn’s Disease Pipeline Therapeutics Assessment

• Crohn’s Disease Assessment by Product Type

• Crohn’s Disease By Stage and Product Type

• Crohn’s Disease Assessment by Route of Administration

• Crohn’s Disease By Stage and Route of Administration

• Crohn’s Disease Assessment by Molecule Type

• Crohn’s Disease by Stage and Molecule Type

DelveInsight’s Crohn’s Disease Report covers around 80 + products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies

Some of the key companies in the Crohn’s Disease Therapeutics Market include:

Key companies developing therapies for Crohn’s Disease are – Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.

Crohn’s Disease Pipeline Analysis:

The Crohn’s Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.

• Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies

Crohn’s Disease Pipeline Market Drivers

• High prevalence of Crohn’s Disease, increase in Drug Development for Crohn’s treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn’s Disease Market.

Crohn’s Disease Pipeline Market Barriers

• However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn’s Disease Market growth.

Scope of Crohn’s Disease Pipeline Drug Insight    

• Coverage: Global

• Key Crohn’s Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others

• Key Crohn’s Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others

• Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies

• Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers 

Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials

Table of Contents 

1. Crohn’s Disease Report Introduction

2. Crohn’s Disease Executive Summary

3. Crohn’s Disease Overview

4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Crohn’s Disease Pipeline Therapeutics

6. Crohn’s Disease Late Stage Products (Phase II/III)

7. Crohn’s Disease Mid Stage Products (Phase II)

8. Crohn’s Disease Early Stage Products (Phase I)

9. Crohn’s Disease Preclinical Stage Products

10. Crohn’s Disease Therapeutics Assessment

11. Crohn’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Crohn’s Disease Key Companies

14. Crohn’s Disease Key Products

15. Crohn’s Disease Unmet Needs

16 . Crohn’s Disease Market Drivers and Barriers

17. Crohn’s Disease Future Perspectives and Conclusion

18. Crohn’s Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services